Shandong Jincheng Pharmaceutical Group Co., Ltd

SZSE:300233 Stock Report

Market Cap: CN¥4.2b

Shandong Jincheng Pharmaceutical Group Valuation

Is 300233 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300233 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300233 (CN¥11.29) is trading below our estimate of fair value (CN¥12.32)

Significantly Below Fair Value: 300233 is trading below fair value, but not by a significant amount.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300233?

Other financial metrics that can be useful for relative valuation.

300233 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.1x
Enterprise Value/EBITDA6.9x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 300233's PE Ratio compare to its peers?

The above table shows the PE ratio for 300233 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average26.2x
301211 Hubei Biocause Heilen Pharmaceutical
30.9xn/aCN¥4.1b
600488 Tianjin Tianyao Pharmaceuticals
31xn/aCN¥4.2b
603566 Pulike Biological Engineering
30.5x27.8%CN¥4.1b
600479 ZhuZhou QianJin PharmaceuticalLtd
12.6xn/aCN¥4.0b
300233 Shandong Jincheng Pharmaceutical Group
21xn/aCN¥4.3b

Price-To-Earnings vs Peers: 300233 is good value based on its Price-To-Earnings Ratio (21x) compared to the peer average (26.2x).


Price to Earnings Ratio vs Industry

How does 300233's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.4%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.4%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 300233 is good value based on its Price-To-Earnings Ratio (21x) compared to the CN Pharmaceuticals industry average (25.4x).


Price to Earnings Ratio vs Fair Ratio

What is 300233's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300233 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 300233's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies